share_log

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

奥本海默以优于大盘的评级启动对Clarus治疗公司Hldgs的覆盖,宣布目标价为12美元
Benzinga Real-time News ·  2021/09/20 08:19

Oppenheimer analyst Leland Gershell initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Outperform rating and announces Price Target of $12.

奥本海默分析师Leland Gershell以优于大盘的评级启动了Clarus Treateutics Hldgs(纳斯达克市场代码:CRXT)的报道,并宣布目标价为12美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发